Chinese Journal of Contemporary Neurology and Neurosurgery (May 2021)

Associated factors for quality of life in patients with progressive supranuclear palsy

  • CHEN De⁃zhi,
  • OU Ru⁃wei,
  • WEI Qian⁃qian,
  • HOU Yan⁃bing,
  • ZHANG Ling⁃yu,
  • LIU Kun⁃cheng,
  • JIANG Zheng,
  • LIN Jun⁃yu,
  • LIU Jiao,
  • YANG Tian⁃mi,
  • YANG Jing,
  • SHANG Hui⁃fang

DOI
https://doi.org/10.3969/j.issn.1672⁃6731.2021.05.014
Journal volume & issue
Vol. 21, no. 05
pp. 411 – 415

Abstract

Read online

Objective To explore the associated factors for quality of life in patients with progressive supranuclear palsy (PSP). Methods A total of 218 PSP patients were included from January 2012 to December 2019. Demographic and clinical data were collected. The quality of life was evaluated by the 39⁃Item Parkinson's disease Questionnaire (PDQ⁃39). The Progressive Supranuclear Palsy Rating Scale (PSPRS) was used to assess the severity of PSP related motor and non⁃motor symptoms, while the Non⁃Motor Symptoms Scale (NMSS) was used to elevate the non⁃motor symptoms, Hamilton Depression Rating Scale⁃24 (HAMD⁃24), Hamilton Anxiety Rating Scale (HAMA), Lille Apathy Rating Scale (LARS), Frontal Assessment Battery (FAB), and Montreal Cognitive Assessment (MoCA) were used. The Pearson and partial correlation followed by the multiple linear regression were used to explore the correlates of the PDQ⁃39 score. Results Correlation analysis indicated that the PDQ⁃39 score was positively correlated with disease duration (r=0.301, P=0.000), Charlson Comorbidity Index (CCI; r=0.147, P=0.031), levodopa equivalent daily dose (LEDD; r=0.225, P=0.001), and scores for the PSPRS (r=0.551, P=0.000), NMSS (r=0.484, P=0.000), HAMD⁃24 (r=0.515, P=0.000), HAMA (r=0.439, P=0.000) and LARS (r=0.476, P=0.000), but was negatively correlated with scores of FAB (r=⁃0.325, P=0.000) and MoCA (r=⁃0.355, P=0.000). Multiple linear stepwise regression model indicated that the PDQ⁃39 score was significantly associated with female (P=0.021), longer disease duration (P=0.026), higher LEDD (P=0.008), higher PSPRS score (P=0.000), higher NMSS score (P=0.002), higher HAMD⁃24 score (P=0.004), and higher LARS score (P=0.000). Conclusions Female, longer disease duration, higher LEDD, and more severe motor and non⁃motor symptoms contribute to the reduced quality of life in patients with PSP. Our study is beneficial to the clinical management of patients with PSP.

Keywords